Acutaas Chemicals Q4 FY26 Revenue Surges 40.3% YoY to ₹432.8 Crore; PAT Up 114.1%
Acutaas Chemicals reported Q4 FY26 revenue of ₹432.8 crore, up 40.3% YoY, and PAT of ₹134.3 crore, up 114.1% YoY with margins at 31.0%. FY26 revenue was ₹1,339.4 crore (up 33.0% YoY) and PAT was ₹356.4 crore (up 122.2% YoY). The company expects 25% revenue growth in FY27.
Significant year-on-year growth in key financial metrics like revenue and profit, coupled with a positive future growth outlook, is expected to have a high impact on investor sentiment and the company's stock performance.
The company reported strong year-on-year growth in revenue and profit, alongside improved margins and a positive outlook for the next fiscal year.
Acutaas Chemicals Limited (formerly Ami Organics Limited) announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a significant year-on-year (YoY) growth, with Q4 FY26 revenue from operations reaching ₹4,328 million (₹432.8 crore), an increase of 40.3% compared to the same period last year. Profit After Tax (PAT) for the quarter surged by 114.1% YoY to ₹1,343 million (₹134.3 crore), resulting in PAT margins of 31.0%.
For the full fiscal year FY26, revenue from operations grew by 33.0% YoY to ₹13,394 million (₹1,339.4 crore), while PAT saw a substantial increase of 122.2% YoY to ₹3,564 million (₹356.4 crore). The company highlighted improvements in gross margins, which rose to 62.0% in Q4 FY26 from 47.3% in Q4 FY25, and EBITDA, which grew by 116.0% YoY to ₹1,835 million (₹183.5 crore) with an EBITDA margin of 42.4%.
Mr. Naresh Patel, Executive Chairman & Managing Director, expressed satisfaction with the strong close to FY26, emphasizing the company's strategy to build a diversified chemicals business across three high-growth verticals: Battery Chemicals, Semiconductors, and Pharmaceutical CDMO. He expressed confidence in delivering 25% revenue growth in FY27.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.